Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 5519 results found since Jan 2013.

Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study
Discussion: The results of the TRACE study will provide preliminary evidence for the relationship between XNJI used within 24 h of onset and the presence of END on the third day after stroke onset; it will aid in improving the current knowledge regarding the early use of XNJI for stroke first aid.Clinical Trial Registration:clinicaltrials.gov, identifier NCT04275349
Source: Frontiers in Pharmacology - August 29, 2022 Category: Drugs & Pharmacology Source Type: research

Network pharmacology and experimental study of phenolic acids in salvia miltiorrhiza bung in preventing ischemic stroke
At present, the preventive effect of ischemic stroke is not ideal, and the preventive drugs are limited. Danshen, the dried root of Salvia miltiorrhiza Bge, is a common medicinal herb in Traditional Chinese Medicine, which has been used for the treatment of cardiovascular diseases for many years. Phenolic Acids extracted from danshen, which showed multiple biological activities, have been developed as an injection for the treatment of ischemic stroke. However, its preventive effect on ischemic stroke has not been fully reported. The current study aimed to identify the potential active phenolic acids for the prevention of i...
Source: Frontiers in Pharmacology - January 27, 2023 Category: Drugs & Pharmacology Source Type: research

The Relationship of Astrocytes and Microglia with Different Stages of Ischemic Stroke
CONCLUSION: Understanding the details of astrocyte-microglia interaction processes will contribute to a better understanding of the mechanisms underlying ischemic stroke, contributing to the identification of new therapeutic interventions.PMID:37464832 | DOI:10.2174/1570159X21666230718104634
Source: Current Neuropharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Zhen Liang Yingyue Lou Yulei Hao Hui Li Jiachun Feng Songyan Liu Source Type: research

Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population.
CONCLUSIONS: More than half of patients on warfarin had treatment gaps or discontinued therapy. Therapy gaps were associated with increased stroke risk. PMID: 23867114 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - July 15, 2013 Category: Drugs & Pharmacology Authors: Deitelzweig SB, Buysman E, Pinsky B, Lacey M, Jing Y, Wiederkehr D, Graham J Tags: Clin Ther Source Type: research

Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies.
Abstract Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of...
Source: Current Vascular Pharmacology - January 1, 2014 Category: Drugs & Pharmacology Authors: Tuttolomondo A, Pecoraro R, Di Raimondo D, Arnao V, Clemente G, Corte VD, Maida C, Simonetta I, Licata G, Pinto A Tags: Curr Vasc Pharmacol Source Type: research

Is Sodium Valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case–control study
ConclusionSodium valproate exposure was associated with the risk of MI, but not ischemic stroke. However, longer exposure to SV was associated with lower odds of stroke, but this might be explained by survivor bias. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - May 1, 2014 Category: Drugs & Pharmacology Authors: Alex Dregan, Judith Charlton, Charles D. A. Wolfe, Martin C. Gulliford, Hugh S. Markus Tags: Original Report Source Type: research

Genetic Signatures in the Treatment of Stroke.
Abstract Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an intricate interplay of environmental and genetic factors. Genes not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and may also influence the clinical outcome of the disease. Current treatment strategies for stroke include tissue plasminogen activator, antiplatelet agents and lipid lowering drugs. These act via diverse mechanisms of actions and are centered around the management of modifiable risk factors to prevent the recurrent stroke events. H...
Source: Current Pharmaceutical Design - August 26, 2014 Category: Drugs & Pharmacology Authors: Munshia A, Sharma V Tags: Curr Pharm Des Source Type: research

Decreased risk of stroke in patients receiving traditional Chinese medicine for vertigo: A population-based cohort study
Conclusions Results of this population-based study support the effects of TCM on reducing stroke risk, and may provide a reference for stroke prevention strategies. The study results may also help to integrate TCM into clinical intervention programs that provide a favorable prognosis for vertigo patients. Graphical abstract
Source: Journal of Ethnopharmacology - March 22, 2016 Category: Drugs & Pharmacology Source Type: research

Association of High Homocysteine Levels With the Risk Stratification in Hypertensive Patients at Risk of Stroke.
Abstract PURPOSE: We aimed to investigate the association between stroke morbidity and different stratifications of classic risk factors, such as increasing age, body mass index (BMI), blood lipids, and blood glucose, in hypertensive patients with high homocysteine levels. METHODS: A cross-sectional study of 2258 patients with primary hypertension were enrolled in this study, including 871 stroke cases (62.89%) in 1385 hypertensive patients without hyperhomocysteinemia (HHcy) and 647 (74.11%) stroke cases in 873 hypertensive patients with HHcy. Basic information of patients were collected, including age, sex,...
Source: Clinical Therapeutics - March 23, 2016 Category: Drugs & Pharmacology Authors: Pang H, Han B, Fu Q, Zong Z Tags: Clin Ther Source Type: research

Dipyrone comedication in aspirin treated stroke patients impairs outcome.
CONCLUSIONS: Dipyrone comedication in patients with stroke impairs pharmacodynamic response to aspirin. This is associated with worse clinical outcome. Therefore dipyrone should be used with caution in aspirin treated stroke patients. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/show/NCT02148939; Identifier: NCT02148939. PMID: 27301652 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - June 10, 2016 Category: Drugs & Pharmacology Authors: Dannenberg L, Erschoff V, Bönner F, Gliem M, Jander S, Levkau B, Kelm M, Hohlfeld T, Zeus T, Polzin A Tags: Vascul Pharmacol Source Type: research

Targeting the role of lipoprotein (a) in stroke.
Authors: Garelnabi M, Mazhar Z, Hughes A Abstract Stroke is the third leading cause of death in the United States, behind only heart disease and cancer, with over 140,000 associated deaths per year. Considerable research is ongoing to examine the role of modifiable risk factors which may cause or contribute to a stroke occurring. Although age and family history are generally considered to be major risk factors, there are several modifiable and non-modifiable risk factors that are linked to the pathogenesis of a stroke. Lipoprotein (a), or Lp(a), is a type of low-density lipoprotein containing an integral apoB100 co...
Source: Cardiovascular and Hematological Disorders Drug Targets - April 22, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Risks of newly onset hemorrhagic stroke in patients with neovascular age ‐related macular degeneration
ConclusionsPatients with nAMD had a significantly higher risk of developing stroke, which was driven mainly by the increased risk of developing the hemorrhagic subtype.
Source: Pharmacoepidemiology and Drug Safety - August 30, 2017 Category: Drugs & Pharmacology Authors: Wan ‐Ju Annabelle Lee, Ching‐Lan Cheng, Cheng‐Han Lee, Yea‐Huei Kao Yang, Swu‐Jane Lin, Cheng‐Yang Hsieh Tags: ORIGINAL REPORT Source Type: research

Cell-based and pharmacological neurorestorative therapies for ischemic stroke.
Abstract Ischemic stroke remains one of most common causes of death and disability worldwide. Stroke triggers a cascade of events leading to rapid neuronal damage and death. Neuroprotective agents that showed promise in preclinical experiments have failed to translate to the clinic. Even after decades of research, tPA remains the only FDA approved drug for stroke treatment. However, tPA is effective when administered 3-4.5 h after stroke onset and the vast majority of stroke patients do not receive tPA therapy. Therefore, there is a pressing need for novel therapies for ischemic stroke. Since stroke induces rapid...
Source: Neuropharmacology - August 31, 2017 Category: Drugs & Pharmacology Authors: Venkat P, Shen Y, Chopp M, Chen J Tags: Neuropharmacology Source Type: research

Sodium-glucose cotransporter 2 inhibitors and ischemic stroke.
CONCLUSION: Despite the multiple pleiotropic effects of SGLT-2 inhibitors, these agents do not appear to affect stroke risk. Ongoing large trials with longer follow-up will evaluate whether the pleiotropic effects of this class will translate into benefits in ischemic stroke prevention. PMID: 29412119 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research